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CHAPTER I
INTRODUCTION
Defensins are cysteine-rich antimicrobial peptides that vary in length from 63 to
approximately 104 amino acids with a characteristic β-sheet-rich fold. These peptides are
also enriched in hydrophobic and cationic amino acid residues. Defensins have been
found in many species, including insects, mammals, and birds and have acquired the
name ‘defensins’ based on their association with host defence settings [Xiao et al., 2004]
. Defensins, vital contributors to host immune response, are an efficient part of the innate
host defense because of their ability to recognize and neutralize invading microorganisms
quickly, and also contribute to adaptive immunity through their effector and regulatory
functions [Tomas Ganz, 2003].
There are two main subfamilies of defensins, α-defensins, which have only been
identified in mammals, and β-defensins, found throughout vertebrate species. These two
subfamilies of defensins differ in disulfide bridge pairing between cysteine residues; the
disulfide bridge paring is Cys1-Cys6, Cys2-Cys4, and Cys3-Cys5 in α-defensins, whereas
in β-defensins, it is Cys1-Cys5, Cys2-Cys4, and Cys3-Cys6 (the number indicates the
location of the cysteine residue in the amino acid sequence from the N-terminus) [Selsted
et al., 2005]. A third type of defensin, θ-defensins, are encoded by α-defensin-like
precursors and have been found only in primates. In evolutionary terms, all defensin
subfamilies must have evolved from an ancestral β-defensin gene by duplication and
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diversification, since α- or θ-defensins have not been found in phylogenetically much
older vertebrates, such as birds and fish [Semple et al., 2003].
The chicken (Gallus gallus domesticus) genome encodes at least 14 different βdefensins, with no α- or θ-defensin genes being identified [Albert et al., 2008]. The βdefensins in chicken had been previously called gallinacins; however, it has now been
agreed to use their gene names [i.e., avian β-defensins (AvBD)] [Lynn et al., 2007], we
therefore decided to use the new terminology for this study.
Avian β-defensin genes are clustered densely within a 86.0 kb distance on the
chromosome 3q3.5-q3.7 [Lynn et al., 2007], and each gene possesses the same genomic
structure of four exons that are separated by three introns of various lengths with the
exception of AvBD12 gene where the last two exons have fused [ Xiao et al., 2004]. The
1st exon corresponds to the 5′ UTR region, and the 2nd exon encodes the signal peptide
and part of the propiece, while the remaining part of the short propiece and majority of
the mature peptide are encoded by the 3rd exon. The 4th exon encodes the remaining part
of the mature peptide and the 3′ UTR region [Albert et al., 2008].
Although the details of mechanisms ruling the synthesis, storage and activation of
avian β-defensins are lacking, they can be expected to parallel that of mammalian
defensins. Myeloid β-defensins are synthesized in the bone marrow; after biosynthesis
and intracellular trafficking through the Golgi apparatus, the signal peptide ( about 19
amino acids), functioning to anchor the prodefensin peptide in the endoplasmic reticulum
(ER) membrane, is rapidly proteolytically cleaved to generate a prodefensin peptide with
little or no microbicidal activity [Satchell et al., 2003], and the prodefensins are stored
into specific granules as mature peptides [Yount et al., 1999]. Non-myeloid biosynthesis
of β-defensin has been described to some detail for mammalian epithelial cells [Dale et
2

al., 2001; Oren et al., 2003]. In chicken, non-myeloid β-defensin expression has been
found for epithelial cells and tissues [Ohashi et al., 2005; Yoshimura et al., 2006; Zhao et
al., 2001], but data describing their biosynthesis in these cells and tissues has not yet been
reported. Due to the local repertoire of proteolytic enzymes and inhibitors, the proteolytic
processing of avian β-defensin proforms is host and tissue-specific and may result in
multiple forms with different properties. For instance, human epididymis β-defensin-like
peptides are processed by furin-like convertases, which are the major processing enzymes
of the secretory pathway located in the trans-Golgi network [Gu et al., 2001; von Horsten
et al., 2002]. Human β-defensin-1 (hBD-1) produced by oral keratinocytes is processed
into one major form (47 amino acids) and several minor forms (40–44 amino acids)
[Diamond et al., 2001] by yet unidentified proteases, whereas multiple truncated forms of
hBD-1 occurring in plasma can be explained by prodefensin cleavage by a
chymotrypsinlike enzyme [Hiratsuka et al., 2000; Zucht et al., 1998]. Furthermore,
details of avian β-defensin intracellular trafficking, storage and activation in myeloid and
non-myeloid cells are lacking.
Differing in tissue expression, gene regulation, structural properties, and
biological activities, avian β-defensins are found to be constitutively expressed in some
cell populations and tissues, including respiratory tract, skin, digestive tract, urogenital
tract, leukocytes, etc., which are involved in the innate immune response against
microbial infections. For example, avian heterophils, like the neutrophils of some
mammalian species, contain multiple β-defensins [Schneider et al., 2005; Selsted et al.,
1993]. In addition, the expression of avian β-defensins also can be induced or upregulated
in some tissues in response to microbial infection or by proinflammatory stimulants, such
as cytokines (IL-1α, IL-1β, TNF-α, IFN-γ, and TGF-1), LPS, bacteria, yeast and other
3

stimulants such as PMA, isoleucine and 1, 25-dihydroxyvitamin D3 [Albert et al., 2008].
For example, AvBD-3 was significantly upregulated in tracheal tissue in response to
Haemophilus paragallinarum infection, but not in other tissues [Zhao et al., 2001]. Small
intestinal AvBD-4, -5 or -6 mRNA levels were not upregulated in response to an oral
challenge with Salmonella serovars [Panagiota Milona et al., 2007].
Being constitutively or inducibly expressed, avian β-defensins have been shown
to contribute to host innate defense via direct bactericidal activity. These peptides
comprise a N-terminal signal sequence, a propiece, and a C-terminal mature peptide.
Avian β-defensin peptides are highly cationic due to the presence of numerous arginine,
lysine and histidine residues, and they have a three-dimensional amphipathic structure,
i.e. they possess hydrophilic amino acid residues aligned along one side and hydrophobic
amino acid residues aligned along the opposite side. The tertiary structure of these
peptides consists of three antiparallel β-sheets, which are constrained by three
intramolecular disulfide bridges formed by cysteine residues, making up the
characteristic “defensin-like” fold. For most mature avian β-defensins, disulfide bridges
and their connectivity appear not to be important for direct antimicrobial activity, but
may play a prominent role in other functions, such as protection against proteolysis and
chemotaxis [Albert et al., 2008], [Klu¨ver et al., 2005], [Selsted et al., 2005], [Wu et al.,
2003]. On the other hand, the highly variable amino acid composition and positioning
appear to determine the extent to which individual avian β-defensins specifically target
certain types of microorganisms [Torres et al., 2004]. The amphipathic character of avian
β-defensins may be responsible for their antimicrobial activities since they can
favourably attach and insert into their targets, such as bacterial membranes. The initial
contact between the peptide and the target organism is electrostatic, as most bacterial
4

surface components, such as lipopolysaccharides (LPS), lipoteichoic acid (LTA) and
anionic phospholipids, are anionic. During initial electrostatic interactions, avian βdefensins also can competitively displace Ca2+ and Mg2+ ions which are important for
microbial outer membrane stability, due to their higher affinity for divalent cation
binding places. Their amino acid composition, amphipathicity, cationic charge and size
allow avian β-defensins to attach to and insert into membrane bilayers to form pores by
‘carpet wormhole’ model [Ganz, 2003]. Or allow them to penetrate into the cell to bind
intracellular molecules which are crucial to cell living. The intracellular binding model of
avian β-defensins includes inhibition of cell wall synthesis, alteration of cytoplasmic
membrane, activation of autolysin, inhibition of the synthesis of DNA, RNA, and protein,
and inhibition of certain enzymes [Lehrer et al., 1989; Tang et al., 1999]. However, in
many cases, the exact mechanism is not known.
Most avian β-defensins show inhibitory and killing activities against Gramnegative and Gram-positive bacteria (including strains resistant to conventional
antibiotics), mycobacteria (including Mycobacterium tuberculosis), enveloped viruses,
fungi and even transformed or cancerous cells. For example, synthetic chicken AvBD-9
peptide showed strong microbicidal activity against the Gram-negative bacterium
Campylobacter jejuni (3.7 mM), Gram-positive bacteria, Clostridium perfringens, S.
aureus (1.9–3.7 mM) and the yeasts Candida albicans and Saccharomyces cerevisiae
(1.9 mM); additionally, Treatment with synthetic AvBD-9 resulted in a 3 log unit
reduction in Clostridium perfringens survival within 60 min, indicating fast killing
kinetics [Albert van Dijk et al., 2007]. Evans et al. (1995) demonstrated bactericidal and
fungicidal activity of chicken heterophil AvBD1, at peptide concentrations of 0.4–3.4
mM against avian pathogens. However, these peptides were not able to kill Pasteurella
5

multocida or neutralize Infectious Bronchitis Virus, an enveloped coronavirus of
chickens.
In addition to their important roles in innate host defense via direct antimicrobial
activity, avian β-defensins have also been shown to contribute to adaptive immunity
through effector and regulatory functions. They have been demonstrated to have a
number of immunomodulatory functions involved in the clearance of infection, including
the ability to alter host gene expression, act as chemokines and/or induce chemokine
production, inhibit lipopolysaccharide induced pro-inflammatory cytokine production,
promote wound healing and adaptive immunity by selective recruitment by chemotaxis of
monocytes [Territo et al.,1989], T lymphocytes [Chertov et al., 1996], immature dendritic
cells [Yang et al., 1999] and mast cells [Niyonsaba et al., 2002] to sites of inflammation.
Furthermore, they are able to enhance macrophage phagocytosis [Fleischmann et al.,
1985], and to induce histamine release from peritoneal mast cells [Befus et al., 1999].
Identification of these avian β-defensins will aid in the study of the innate and
adaptive immune response of the chicken, an economically important species. Moreover,
these novel antimicrobial peptides may be exploited for the development of new
therapeutic agents for economically significant chicken diseases such as coccidiosis,
which results in a loss to the world poultry industry that is estimated at $700 million
annually [David et al,. 2004]. These peptides could be potentially developed as natural
alternatives to the artificial antibiotics that are commonly fed to chickens and which are
of growing public concern. For these peptides, there are several different potential
strategies for their general therapeutic application: 1) as immunostimulatory agents that
enhance natural innate immunity, 2) as single anti-infective agents, 3) in combination
with conventional antibiotics or antivirals to promote any additive or synergistic effects,
6

and 4) as endotoxin-neutralizing agents to prevent the potentially fatal complications
associated with bacterial virulence factors causing septic shock. Despite many attractive
attributes, the challenges of bringing a successful avian β-defensins to market remain
formidable [Gordon et al., 2005].
Focusing on the three avian β-defensins, AvBD-2, -6, and -12, differing in their
charge, we report here on their in vitro expression, purification, and antimicrobial
activities against food-borne pathogens. The hexahistidine-tagged mature AvBD peptides
were expressed in Escherichia coli (E. coli) BL21(DE3)plysS and affinity-purified by
immobilized-metal (Ni2+) affinity column chromatography. The growth inhibitory and
killing properties of recombinant AvBDs (rAvBDs), determined by colony counting
assay, were tested against E. coli, Salmonella enterica serovar Typhimurium, and
Staphylococcus aureus. For practical purposes, the nomenclature of chicken β-defensin
and related sequences in this paper is based on the recently proposed update of the avian
β-defensin nomenclature by Lynn et al [Lynn et al., 2007].
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CHAPTER II
MATERIALS AND METHODS
2.1

Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Chicken oviduct epithelial cells were cultured and infected as described

previously [Li et al., 2009]. Total RNA was extracted from the infected cells using
TRIzol® Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instruction.
Before reverse transcription, RNA was treated with RNase-free DNase I (Ambion) to
remove DNA contamination. First-strand cDNA was synthesized by using Taqman®
Reverse Transcription Reagents (Applied Biosystems) and reverse transcription was
performed at 25°C for 10 min, 48°C for 45 min, followed by heat inactivation for 10 min
at 95°C. The resulting cDNA was used as templates for subsequent PCR amplification of
gene fragments encoding the mature peptide of AvBD-2, -6, and -12. PCR primers are
listed in Table1. PCR was performed using a DNA Taq polymerase (Sigma, St. Louis,
MO) under the following amplification conditions: 95°C denaturation for 3 min, followed
by 35 cycles of 95°C denaturation for 30 sec, annealing for 20 sec, and 72°C extension
for 30 sec, and a final extension at 72 °C for 5 min. The annealing temperature was
optimized for each gene.
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Table 2.1
Gene
AvBD-2

Primer Sequences Used for Reverse-Transcription (RT)-PCR Analyses

Primer sequence (5′-3′)
Forward---GATGGGGATCCCGGGACATGCTGTTCTGT
Reverse---TCCATGGTACCTTATGCATTCCAAGGCCA
AvBD-6
52
Forward---GATGGGGATCCAGCCCTATTCATGCTTGTAG
Reverse---TCCATGGTACCTCAGGCCCACCTGTTC
AvBD-12
52
Forward---GATGGGGATCCGGCCCAGACAGCTGTAAC
Reverse---TCCATGGTACCTCAGGTCTTGGTGGGAG
Note: The forward primers contain a BamH I restriction site (GGATCC) and the reverse
primers a Kpn I restriction site (GGTACC), which are underlined. T (°C) represents the
optimum annealing temperature for PCR analyses.
2.2

T(°C)
55

Plasmids Construction
RT-PCR products, including AvBD-2, AvBD-6, and AvBD-12, were separated on

a 1.5% Agarose/EtBr gel and visualized using the AlphaImager system (Alpha Innotech).
DNA bands with expected sizes were excised from the gel and DNA was purified from
gel by using the Wizard® PCR prep DNA purification system (Promega, Madison, WI).
The purified PCR products were cloned into pCR 2.1-TOPO® (Invitrogen, Carlsbad, CA)
to generate plasmids pCR2.1-AvBD-2, pCR2.1-AvBD-6, and pCR2.1-AvBD-12,
respectively. The resultant plasmids were transformed into E. coli TOPO10 according to
the manufacturer’s instructions (Invitrogen, Carlsbad, CA). The transformed cells were
selected on LB agar containing 50µg/ml ampicillin and 30µg/ml X-gal. Clones with
inserts were screened by colony-lysis PCR. E. coli TOPO10 strains harboring plasmids
pCR2.1-AvBD-2, pCR2.1-AvBD-6, and pCR2.1-AvBD-12 were designated as ZM-50,
ZM-51, and ZM-52, respectively. Subsequently, the cloned gene fragments were excised
from pCR2.1-AvBD-2, pCR2.1-AvBD-6, and pCR2.1-AvBD-12 by restriction
endonuclease digestion with BamH I (Promega, Madison, WI) and Kpn I (Promega,
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Madison, WI) and subcloned into the corresponding sites of pRSET A, a protein
expression vector, by using T4 DNA ligase (Invitrogen, Carlsbad, CA). The resultant
plasmids, designated as pRSET A-AvBD-2, pRSET A-AvBD-6, and pRSET A-AvBD12, respectively, were transformed into E. coli BL21(DE3)plysS. The transformed E. coli
cells were selected on LB agar containing 50 µg/ml ampicillin and 35 µg/ml
chloramphenicol. E. coli BL21(DE3)plysS strains harboring pRSET A-AvBD-2, pRSET
A-AvBD-6, and pRSET A-AvBD-12, were designated as ZM-51E, ZM-52E, and ZM53E, respectively. Plasmids were purified using the Wizard® Plus Minipreps DNA
Purification System (Promega, Madison, WI) and sequenced commercially (Eurofins
MWG Operon, Huntsville, AL ) to confirm the correctness of the inserts.
2.3

Protein Expression
A single colony from fresh cultured LB agar plate was inoculated into 10 ml SOB

containing 50 µg/ml ampicillin and 35 µg/ml chloramphenicol and incubated overnight at
37°C with vigorous shaking (220 rpm). The overnight culture was then added into 1 L
SOB without antibiotics to an OD600 of 0.1. The inoculated culture was incubated at 37°C
with vigorous shaking (220 rpm) to an OD600 of 0.4 - 0.6 at which time isopropyl-β-Dthiogalactopyranoside (IPTG) is added to a final concentration of 0.2 mM to induce the
expression of 6xHis-tagged avian β-defensin peptides. After an additional 2-hour
incubation at 37°C with shaking, induced bacteria were harvested by centrifugation at
3,000 g for 10 minutes at 4 ºC. The pellet was resuspended in 20ml buffer B (7 M urea,
0.1 M NaH2PO4, 0.01 M Tris-HCl, pH 8.0). The bacterial suspension was sonicated for
10 minutes at 20 kHz using 1 s-1 pulse and 30 - 40% acoustic power and centrifuged at
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13,000 g for 10 minutes to remove cell debris. The supernatant fraction was stored at -20
ºC prior to protein purification.

Figure 2.1

Map of pRSET A Vecto

Note: T7 promoter: bases 20-39
6xHis tag: bases 112-129
XpressTM epitope: bases 169-192

Multiple cloning site: bases 201-248
Ampicillin resistance gene: bases 1042-1902

2.4

Purification of Recombinant Avian β-defensins (rAvBDs)
Purification of the recombinant peptide was performed by affinity

chromatography using Ni2+-NTA anti-His protein superflow columns (Qiagen sciences,
Germantown, MD). The supernatant fraction of bacterial lysate (10 ml) was applied to
the column, which was subsequently washed with buffer C (7 M urea, 0.1 M NaH2PO4,
11

0.01 M Tris-HCl, pH 6.3). The membrane-bound 6xHis-tagged peptides were eluted with
5 ml buffer E (8 M urea, 0.1 M NaH2PO4, 0.01 M Tris-HCl, pH 4.5). The peptide
solution was added into a Slide-A-Lyzer dialysis cassette (molecular mass cutoff 2,000
Da, Fisher scientific, Pittsburgh, PA) and dialyzed sequentially against the peptide buffer
(50 mM NaCl and 20 mM Tris-HCl) containing 6 M, 4 M, 2 M urea for 4 hours each
time and finally the peptide buffer without urea for 12 hours at 4 ºC.
Phenylmethylsulfonyl Fluoride (PMSF) (Fisher scientific, Pittsburgh, PA) was added into
all buffer systems to a final concentration of 1 mM to prevent protein degradation.
Following dialysis, the recombinant peptides were concentrated using a Microcon
Centrifugal Filter devices (Molecular mass cutoff = 3,000 Da, Fisher Scientific,
Pittsburgh, PA). The protein concentrations were determined by measuring the
absorbance at 280 nm.
2.5

Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
and Western-Blot Analysis
Recombinant 6xhis-tagged peptides were separated on 16.5% (wt/vol)

polyacrylamide gel and transferred electrophoretically onto 0.2 µm nitrocellulose
membrane (Bio-Rad Laboratories, Richmond, CA). The membrane was blocked in
phosphate-buffered saline (PBS) containing 0.05% (vol/vol) Tween 20 and 5% (wt/vol)
milk powder for 1 hour at room temperature with gently agitation. Following 3 washes
for 5 minutes each with PBS-Tween 20 (0.05%), the membrane was incubated in antiXpress primary antibody (1:2000 dilution in blocking solution) (Invitrogen, Carlsbad,
California) for 1 hour at room temperature with gentle agitation. The membrane was
washed 3 times for 5 minutes each with PBS-Tween 20 (0.05%) and incubated in antimouse IgG-HRP conjugate (1:500 dilution in blocking solution) (Promega, Madison, WI)
12

for 1 hour at room temperature with gentle agitation. Detection of recombinant peptides
was achieved by visualization of color after development in 4-chloro-1-naphthol (SigmaAldrich, St. Louis, MO) and 30% hydrogen peroxide (Sigma-Aldrich, St. Louis, MO).
2.6

Analysis of rAvBD Characteristics
The molecular mass and hydrophobicity of rAvBD-2, -6, and -12 were calculated

using the peptide property calculator (GenScript). The net charge at pH6 and pH7 were
calculated using the protein calculator v3.3
(http://www.scripps.edu/~cdputnam/protcalc.html.).
2.7

Antimicrobial activity
Colony-counting method was used to determine the antimicrobial activities of

AvBDs against Staphylococcus aureus (S. aureus) ATCC 29213, Salmonella enterica
serovar Typhimurium ATCC 14028, and E. coli ATCC 25922. Bacterial cultures were
maintained on LB agar plates at 37°C. To evaluate the inhibitory activities, 3 to 5
colonies from fresh culture plate (< 24 hours) were resuspended in 5 ml sterile distilled
water to achieve a McFarland standard of 0.5 (~108 CFU/ml). Ten µl bacterial suspension
was inoculated into 10 ml Mueller-Hinton broth to obtain a final concentration of
approximately 105 CFU/ml. Equal volumes (25 µl) of bacterial suspension and rAvBD at
varying concentrations were mixed in the wells of a 96-well plate. The final peptide
concentrations were 8 µg/ml, 16 µg/ml, and 32 µg/ml. The bacteria-peptide mixtures
were incubated at 37°C for 3 hours and serially diluted in PBS. Fifty microliters of each
dilution was plated on LB agar plate and incubated at 37ºC for 24 hours. Colonies on
each plate were counted after incubation. To investigate the synergistic antimicrobial
activities of rAvBDs, different combinations of rAvBDs at a final concentration of 16
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µg/ml were tested against S. aureus, S. enterica serovar Typhimurium, and E. coli. The
antimicrobial assays for combined AvBDs were performed as described for individual
AvBDs. For negative control, 25 µl peptide buffer (20 mM Tris-HCl, 50 mM NaCl) was
used to replace rAvBD. The percentage of inhibition was calculated using the following
formula: [CFU (control) - CFU (treatment)] / CFU (control) %. The experiments were
repeated three times with duplicate wells in each experiment.
The killing activities of rAvBDs were determined using bacterial suspensions
prepared in 100x diluted Mueller Hinton broth (1 ml broth in 99 ml distilled water).
Bacterial growth in 100x diluted Mueller Hinton broth was pretested by colony-counting
method. To perform killing assays, equal volumes (25 µl) of bacterial suspension
containing 105 CFU/ml and rAvBDs at varying concentrations were mixed and incubated
at 37ºC for 3 hours. Ten-fold serially diluted peptide-bacteria mixtures were plated on LB
agar plates followed by colony enumeration. To investigate the effect of pH and the
incubation time on the antimicrobial activities of rAvBDs, equal volumes (25 µl) of
bacterial suspension in 100x diluted Mueller Hinton broth and rAvBDs at a final
concentration of 16 µg/ml were coincubated for various times. The reaction mixtures
were 10-fold serially diluted and plated on LB agar plates for colony counting. For
negative controls, 25 µl peptide buffer (20 mM Tris-HCl, 50 mM NaCl) was used to
replace rAvBD to treat bacteria. The killing activity was calculated using the following
formula: [CFU (control) - CFU (treatment)] / CFU (control) %. The experiments were
repeated three times with duplicate wells in each experiment.
The antimicrobial killing kinetics were determined by incubating equal volumes
(25 µl) of bacterial suspension prepared in 100x diluted Mueller Hinton broth and
rAvBDs at a final concentration of 16 ug/ml at 37°C for various times (30, 60, 90, 120,
14

150 min). After incubation, 10-fold serial dilutions were plated on LB agar plates and
incubated at 37C for 24 hours followed by CFU enumeration. The effect of pH on the
antimicrobial activity of rAvBDs was evaluated by conducting the killing assays at pH6
and pH 7. All experiments were repeated three times with duplicate wells in each
experiment.
2.8

Statistical Analysis
The mean value of data collected from three independent experiments and the

standard deviation were calculated by using SAS9.1 software. The differences in the
antimicrobial activities among individual rAvBDs and rAvBD combination groups were
determined using the SAS9.1 software with t test program.
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CHAPTER III
RESULTS
3.1

Amplification of AvBD Genes
Marker AvBD12 AvBD6 AvBD2 β -actin
bp
1,353
1,078
872
603

310
271-281
234
194
118
72

Figure 3.1

Electrophoresis of RT-PCR products.

Note: Total RNA was extracted from chicken oviduct epithelial cells infected with
Salmonella enterica serovar Typhimurium. Two-step RT-PCR was carried out to amplify
gene fragments encoding mature peptides of AvBD-2, -6, and -12. The amplified
products were subjected electrophoresis on 1.5% agrose gel. The sizes of AvBD-2, -6 and
-12 are 120, 129 and 138 bp, respectively. Chicken β-actin (95 bp) cDNA was used as a
control.
RT-PCR was conducted to amplify the gene fragment encoding mature peptide
AvBD-2, -6, or -12. Electrophoresis of RT-PCR products (Figure 2) showed DNA bands
with expected sizes of 120 base pair (bp) for AvBD-2, 129 bp for AvBD-6, and 138 bp
for AvBD-12. The amplified cDNA was directionally cloned into the bacterial expression
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vector pREST A. The orientation and the identities of the cloned AvBD gene fragments
were confirmed by sequence analysis.
3.2

Expression and Characterization of rAvBDs
AvBD-2, -6, and -12 were expressed in E. coli strain BL21(DE3)plysS cells as N-

terminal 6xhis-tagged recombinant peptides and purified by Ni-NTA affinity
chromatography. The yields of rAvBD-2, -6, and -12 were typically 0.92 mg, 1.24 mg,
and 1.52 mg per liter of bacterial culture, respectively. The rAvBD-2, rAvBD-6, and
rAvBD-12 contained N-terminal 6xhis, leader peptide for periplasmic targeting, and the
XpressTM epitope (a total of 35 amino acid residues) and 39, 42, and 45 amino acid
residues specific to AvBD-2, AvBD-6, and AvBD-12, respectively (Table 2). With or
without the N-terminal tag/epitope derived from pRSET A, rAvBD-2 was most
hydrophobic, followed by rAvBD-6 and then rAvBD-12 wherease rAvBD-6 exhibited
the highest net charge at both pH 7 and pH 6 followed by rAvBD-2 and then AvBD-12.
The predicted properties of all three rAvBDs were summarized and presented in Table 3.
SDS and Western analyses of recombinant peptides revealed bands of approximately 10
kDa, consistent with the predicted sizes of 8.447 kDa for rAvBD-2, 8.867 kDa for
rAvBD-6, and 9.022 kDa for rAvBD-12.
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Table 3.1

Amino Acid Sequences of Recombinant Hexahistidine-tagged Mature
AvBDs*

Peptide
Amino acid sequence
6xhis-tag MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGS
AvBD-2 RDMLFCKGGSCHFGGCPSHLIKVGSCFGFRSCCKWPWNA
AvBD-6 SPIHACRYQRGVCIPGPCRWPYYRVGSCGSGLKSCCVRNRWA
AvBD-12 GPDSCNHDRGLCRVGNCNPGEYLAKYCFEPVILCCKPLSPTPTKT
*The 6xHis tag, leader peptide, and the XpressTM Epitope region is underlined. Cysteine
residues are bolded.
Table 3.2

The Predicted Characteristics of Recombinant AvBDs*

Characteristic
Length (aa)

Peptid
AvBD-2
AvBD-6
AvBD-12
6xhis-tagged
75.00
78.00
81.00
Mature
39.00
42.00
45.00
Molecular mass (kDa)
6xhis-tagged
8.45
8.87
9.02
Mature
4.32
4.74
4.90
Hydrophobicity (%)
6xhis-tagged
24.00%
23.00%
20.00%
Mature
28.00%
26.00%
22.00%
Net charge at pH 6.0
6xhis-tagged
8.20
10.40
4.50
Mature
5.50
7.70
1.80
Net charge at pH 7.0
6xhis-tagged
3.70
6.40
0.40
Mature
4.20
7.00
1.00
e property calculator (GenScript). The net charge was calculated using protein calculator
v3.3. *The molecular masse and hydrophobicity were calculated using the peptid
3.3

Bacterial growth inhibition by rAvBDs
Since the antimicrobial potency has been shown previously not to be significantly

altered by the presence of a hexahistidine tag [S.Yenugu et al., 2003], the 6xhis-tagged
recombinant peptides were used to determine the antimicrobial activities of AvBD-2,
AvBD-6, and AvBD-12. At 8, 16, and 32 µg/ml, all three recombinant peptides exhibited
inhibitory active against both gram-positive (Staphylococcus aureus) and gram-negative
bacteria (E. coli and Salmonella enterica serovar Typhimurium) which, however, were
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not concentration-dependent (Figure 3). At 8 and 16 µg/ml, rAvBD-6 was more effective
than rAvBD-2 and rAvBD-12 in inhibiting the growth of S. aureus and E. coli. In
contrast, rAvBD-2 and rAvBD-12 were more potent than rAvBD-6 against S. enterica
serovar Typhimurium (Figure 3). In general, rAvBDs showed highest inhibitory activity
against S. aureus and lowest against S. enterica serovar Typhimurium.

Inhibition%
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Inhibitory activity of rAvBDs against S. aureus

80

rAvBD-2

60

rAvBD-6
rAvBD-12

40
20
0
8 µg/ml

16 µg/ml

32ug/ml

Peptide concentration

Inhibition%
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Inhibitory activity of rAvBDs against E. coli
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16 µg/ml

32 µg/ml
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Figure 3.2

Inhibitory activities of rAvBDs against S. aureus, E. coli, and S. enterica
serovar Typhimurium. Equal volumes (25 μl) of bacterial suspension (105
CFU/ml) in Mueller Hinton broth and rAvBD (105 CFU/ml) were
coincubated at 37°C for 3 hours followed by colony enumerations. Data
shown (bars) are geometric means of three independent experiments ±
standard deviation.
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Figure 3.2 Continued

To investigate whether the three rAvBDs work synergistically or antagonistically,
the combined growth inhibitory activity of different rAvBDs (final concentration
16µg/ml) against S. auereus, E. coli, and S. enterica, serovar Typhimurium were
determined. No significant synergism between any rAvBDs against any bacterial species
was observed. When rAvBD-2 and rAvBD-12 were combined, antagonistic activities
against S. aureus were observed, compared to rAvBD-2 (p=0.018) and rAvBD-12
(p=0.018) alone, and against S. enterica serovar Typhimurium, compared to AvBD-2
(p=0.009) and rAvBD-12 alone (p=0.023). No antagonistic effect against E. coli was
detected between rAvBD-2 and rAvBD-12. No antagonistic activities against the
bacterial species tested were found between rAvBD-6 and rAvBD-12 or rAvBD-2 and
rAvBD-6 (Figure 4).
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Combined inhibitory activity of rAvBDs against S. aureus
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Combined inhibitory activities of rAvBDs against S. aureus, E. coli, and S.
enterica serovar Typhimurium. Equal volumes (25 μl) of bacterial
suspension in Mueller Hinton broth (105 CFU/ml) and rAvBD at a final
concentration of 16 μg/ml were coincubated at 37°C for 3 hours followed
by colony enumerations. Data shown (bars) are geometric means of three
independent experiments ± standard deviation.
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Figure 3.3 Continued
3.4

Killing activities of recombinant peptides
To determine whether rAvBDs were bactericidal, killing assays were performed

by incubating the bacteria in diluted Mueller Hinton broth (at a final dilution of 200x)
with or without the presence of rAvBDs. At this dilution, no significant bacterial growth
or death was detected within the time period (3 hours) tested (data not shown). To
determine the effect of pH on the antimicrobial activities of rAvBDS, killing assays were
carried out at both pH 7.0 and pH 6.0.
At pH 7, all three recombinant peptides exhibited killing activities against the
three bacterial species tested with E. coli being most susceptible to rAvBDs. The killing
activities of rAvBD-2 and rAvBD-6 against E. coli and S. aureus were significantly
higher than that of rAvBD-12 whereas rAvBD-12 was slightly more effective than
rAvBD-2 and rAvBD-6 in killing S. enterica serovar Typhimurium. Therefore, the
bactericidal activity of rAvBDs was bacterial species-dependent.
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Stronger bactericidal activities against S. aurues and E. coli were observed for all
three rAvBDs at pH 6.0 than at pH 7.0, indicating a pH-dependent killing mechanism for
these peptide/bacteria combinations. However, reducing pH had no significant effect on
rAvBDs-mediated killing of S. enterica serovar Typhimurium. In fact, rAvBDs
demonstrated minimal bactericidal activity against S. enterica serovar Typhimurium
under both neutral and acidic pH conditions (Figure 5 and 6).
Killing activity of rAvBDs against S. aureus at pH 7.0
100
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rAvBD-12
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Figure 3.4

Killing activities of rAvBDs against S. aureus, E. coli, and S. enterica
serovar Typhimurium at pH 7.0. Equal volumes (25 μl) of bacterial
suspension (105 CFU/ml) in 100x diluted Mueller Hinton broth and rAvBD
at a final concentration of 16 μg/ml were coincubated at 37°C for 3 hours
followed by colony enumerations. Data shown (bars) are geometric means
of three independent experiments ± standard deviation
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Killing activity of rAvBDs against E. coli at pH 7.0
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Figure 3.4 Continued
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32 µg/ml

Killing activity of rAvBDs aginst S. aureus at pH 6.0
100

Killing%

80
60

rAvBD-2

40

rAvBD-6
rAvBD-12

20
0
8 µg/ml

16 µg/ml

32 µg/ml

Peptide concentration
Killing activity of rAvBDs against E. coli pH 6.0
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Figure 3.5

Killing activities of rAvBDs against S. aureus, E. coli, and S. enterica
serovar Typhimurium at pH 6.0. Equal volumes (25 μl) of bacterial
suspension (105 CFU/ml) in 100x diluted Mueller Hinton broth and rAvBD
at a final concentration of 16 μg/ml were coincubated at 37°C for 3 hours
followed by colony enumerations. Data shown (bars) are geometric means
of three independent experiments ± standard deviation.
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Killing activity of rAvBDs against S. enterica serovar
Typhimurium at pH 6.0
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Figure 3.5 Continued
3.5

Killing kinetics of rAvBD
To determine whether the bactericidal activities were time-dependent, killing

assays were performed by treating S. auereus and E. coli with rAvBDs at a final
concentration of 16 µg/ml for various times at either pH 7.0 or pH 6.0. The results
showed that rAvBDs exerted bactericidal effect within 30 minutes of treatment (Figure 7
and Figure 8). A higher percentage of S. aureus than E. coli was killed by rAvBDs within
120 minutes of treatment (Figure 7 and Figure 8). The killing activities of the three
rAvBDs against S. aureus reached their peak between 60 and 120 minutes followed by a
decline at 150 minutes (Figure 7). In contrast, sustained killings of E. coli by the three
rAvBDs were observed within the time period tested (Figure 8). The bactericidal effects
of the rAvBDs were significantly enhanced by decreasing pH. The pH effect was
significantly greater on rAvBD-mediated killing of S. aureus than E. coli (Figure 7 and
Figure 8).
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pH-dependent killing kinetics of rAvBD-2 against S. aureus
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Figure 3.6

pH-dependent killing kinetics of rAvBDs against S. aureus. Equal volumes
(25 μl) of bacterial suspension (105 CFU/ml) in 100x diluted Mueller
Hinton broth and rAvBD at a final concentration of 16 μg/ml were
coincubated at 37°C for various times followed by colony enumerations.
Data shown (line graph) are geometric means of three independent
experiments ± standard deviation.
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pH-dependent killing kinetics of rAvBD-12 against S. auereus
100

Killing %

80
pH=6

60

pH=7

40
20
0
0 min

30 min 60 min

90 min 120 min 150 min

Time Points

Figure 3.6 Continued
pH-dependent killing kinetics of rAvBD-2 against E. coli
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Figure 3.7

pH-dependent killing kinetics of rAvBDs against E. coli. Time-dependent
killing of stationary phase E. coli by recombinant AvBDs at pH 6.0 and
7.0. Equal volumes (25 μl) of bacterial suspension (105 CFU/ml) in 100x
diluted Mueller Hinton broth and rAvBD at a final concentration of 16
μg/ml were coincubated at 37°C for various times followed by colony
enumerations. Data shown (line graph) are geometric means of three
independent experiments ± standard deviation
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pH-dependent killing kinetics of rAvBD-6 against E. coli
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pH-dependent killing kinetics of rAvBD-12 against E. coli
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Figure 3.7 Continued
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CHAPTER IV
DISCUSSION
4.1

The expression of recombinant AvBD-2, -6, and -12 in E. coli.
It has been shown that the chicken genome contains 14 genes encoding avian β-

defensin [Albert et al., 2008]. Some of these defensins have been directly purified from
chicken tissues and others expressed in vitro as recombinant proteins [Harwig et al.,
1994, Milona et al., 2007, and Albert van Dijk et al., 2007]. To understand the local
innate immunity in chicken reproductive system, we have characterized the expression
profiles of all 14 β-defensin genes in chicken oviduct epithelia cells and found that
AvBD-2 and AvBD-6 are induced by Salmonella infection and AvBD-12 is
constitutively expressed [Ebers et al., 2009]. To characterize the biological roles played
by these defensins, we expressed the mature peptides of AvBD-2, -6, and -12 in
BL21(DE3)plysS as recombinant peptides with an N-terminal 6xhis tag. The total yields
of rAvBD-2, -6, and -12 were typically 0.92 mg, 1.24 mg, and 1.52 mg, respectively,
from one liter culture of BL21(DE3)plysS cells.
4.2

Inhibition of bacterial growth by recombinant AvBD-2, -6, and -12.
All three rAvBDs inhibited the growth of S. aureus, E. coli, and S. enterica

serovar Typhimurium which appeared to be peptide- and bacterial species-dependent. In
general, rAvBD-2 and rAvBD-6 were more potent than rAvBD-12 in inhibiting the
growth of S. aureus and E. coli. The inhibitory potency could be characterized as rAvBD6 > rAvBD-2 > rAvBD-12 which coincided with their net charges in the order of 6.40,
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3.70, and 0.40 for 6xhis tagged rAvBD-2, rAvBD-6, and rAvBD-12 or 7.70, 5.50, and
1.80 for mature AvBD-2, AvBD-6, and AvBD-12, respectively. Both rAvBD-2 and
rAvBD-6 were more effective against S. aureus and E. coli than S. enterica serovar
Typhimuirum. This observation is similar to what has been described for rAvBD-9 that
inhibited the growth of E. coli, but not S. enterica serovar Typhimurium [Albert van Dijk,
2007]. In contrast, minimal difference in the inhibitory activity of rAvBD-12 against
different bacterial species was observed and a slightly higher percentage of S. enterica
serovar Typhimurium was inhibited by rAvBD-12 than that by rAvBD-6 which was in
line with previous findings that rAvBD-5 with a lower positive charge (+4) than rAvBD6 (+7) exhibited stronger antimicrobial effects against Salmonella species [Milona et al.,
2007].
It is known that S. enterica has evolved multiple mechanisms to resist
antimicrobial molecules, such as β-defensins [Gunn et al., 2000; Guo et al., 1998,
McPhee et al., 2003]. One mechanism involves the addition of 4-aminoarabinose
(Ara4N) to the phosphate group of the lipid A backbone, for which two genetic loci,
pmrE and pmrHFIJKLM, are required [Gunn et al., 2000]. Another mechanism utelizes
the PhoP-PhoQ regulated pagP gene that functions to increase acylation of lipid A [Gunn
et al., 2000; McPhee et al., 2003]. Interruption of the pagP gene increases the outer
membrane permeability to β-defensins [Guo et al., 1998]. Modifications of the lipid A
reduce the net negative charge of LPS on the surface of S. enterica serovar Typhimurium
which interferes with the initial electrostatic attraction between the bacteria and cationic
peptides, thereby conferring resistance to β-defensins. Understandably, reduction of
charge via modification of lipiA would play a more significant role in avoiding highly
charged cationic peptides than minimally charged peptides, such as AvBD-12 (+0.4). Our
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investigation also found a significant antagonistic effect of rAvbD-2 and AvBD-12 on
their inhibitory activities against S. aureus and S. enterica serovar Typhimurium, but not
E. coli which again highlights the diverse mechanisms underlying the antimicrobial
function of AvBDs. It has been suggested the amphipathicity and size of β-defensins
allow them insert into the membrane of microbes following initial contact [Tomas Ganz.,
2003]. Since the charges of rAvBD-2 and rAvBD-6 are similar and rAvBD-6 does not
work against rAvBD-12, the antagonism between rAvBD-2 and rAvBD-12 can not be
attributed to an interference of charged-based peptide-bacterium attraction. This opens
the possibility of competition by the two rAvBDs for other pathways involved in
bacterial membrane damage or growth inhibition.
4.3

Bacterial killing by rAvBD-2, rAvBD-6, and rAvBD-12.
Data from the present study shows that all three rAvBDs are not only bacterial

static, but also bactericidal. These peptides are more effective in killing E. coli than S.
aureus and S. enterica serovar Typhimurium at pH 7.0. The bactericidal potency of the
peptides against E. coli and S. aureus can be defined as rAvBD-6 > rAvBD-2 > rAvBD12 which again correlates with the net charge of these AvBDs. Consistent with data from
bacterial inhibition assays, rAvBD-12 was slightly more effective in killing S. enterica
serovar Typhimurium. The bactericidal activities against S. aureus and E. coli were pH
dependent as evidenced by the increased killing at pH 6.0, compared to pH 7.0. The
increased killing activities correlated with the elevated charges of rAvBDs at pH 6.0
which favors the attachment of AvBDs to anionic components of bacteria, such as
lipoteichoic acid (LTA) of S. aureus and lipopolysaccharides (LPS) of E. coli. However,
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the bactericidal activity of rAvBD-12 against S. enterica serovar Typhimurium was not
subject to pH change.
4.4

Killing kinetics of rAvBD-2, rAvBD-6, and rAvBD-12.
The killing-curves showed that rAvBDs exerted their antimicrobial function

within 30 minutes of treatment. It is unknown why the killing activity of rAvBDs against
S. aureus declined after certain period of treatment. These assays were conducted by
incubating bacteria in a minimal nutrient medium (Mueller Hinton broth at a final
dilution of 200x) which maintained the viability of bacteria without promoting bacterial
growth within the time of assay. However, it was still possible that the replication of a
resistant population of S. aureus occurred. Similar kinetics has been reported for
synthetic human β-defensins (hBDs). A 1.5 and 1 log unit decrease in survival of S.
aureus cells within 60 min was observed after treatment with synthetic hBD-2 and hBD3, respectively, indicate an effective mechanism of human β-defensins [Sahl et al., 2005].
In addition, examination of synthetic AvBD-9-treated C. perfringens by transmission
electron microscopy showed dose-dependent morphological effects, as seen for other
defensins. A 30-min treatment of 108 CFU/ml C. perfringens cells with synthetic AvBD9 concentrations ranging from 1.56 to 25µg/ml induced dose-dependent changes. At
lower concentrations, clumping of intracellular material and irregular septum formation
during cell division were observed. Most cells showed signs of cytoplasm retraction and
detachment of the cytoplasmic membrane from the peptidoglycan layer at higher
concentrations, sometimes resulting in mesosome-like structures. Prior to complete lysis,
often originating at the cell poles or at the septa of dividing cells, many cells developed a
ghostlike appearance [Albert van Dijk, 2007]. Similar observations were also described
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by Lee et al. (2004), who observed chromatin condensation in Haemophilus influenza
after a 30-min treatment with 10 µg/ml hBD-2 [Lee et al., 2004].
When the influence of pH on killing-curve studies was tested, the results showed
that killing curves were different at two pH levels, and rAvBDs exhibited stronger killing
effects at pH 6.0 at all time points investigated (30, 60, 90, 120, and 150 min). This
indicated that rAvBDs’ killing against stationary phase E. coli and S. aureus was pH
dependent in the range investigated. Similar observations were obtained in killings
assays, which suggested that at pH 6.0, stronger killing potencies of rAvBDs were
observed after three hour incubation of rAvBDs and bacteria cells, E. coli and S. aureus.
4.5

Potential immune functions of AvBD-2, -6, and -12 in chicken cells and
tissues.
The oviduct, consisting of the infundibulum, magnum, isthmus, uterus, and

vagina, can be infected by various microorganisms, including Salmonella enterica
serovars [Barnhart et al., 1993] and Mycoplasma meleagridis [Yamamoto and Herrad,
1966]. Local immunity plays essential roles in preventing infections. Although the
adaptive immune responses have been well characterized [Yoshimura et al., 1997, Zheng
et al., 1997, Zheng et al., 1998, Zheng et al., 1999, and Zheng et al., 2001], less is known
about the components of local innate immunity. Ohashi et al. (2005) reported that all
segments of chicken oviduct express AvBD-1, -2, and -3 with a higher expression in the
infundibulum and vagina [Ohashi et al., 2005]. Yoshimura et al. (2008) showed that 11
out of of 14 AvBD genes, except AvBD-6, AvBD-13, and AvBD-14, are expressed in all
segments of chicken oviduct [Yoshimura et al., 2008]. The expression of AvBD-1, -2,
and -3 are enhanced by exposure to S. enterica serovar Enteritidis and the expression of
AvBD-5, -10, -11, and -12 was induced by LPS stimulation [Yoshimura et al., 2006,
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Yoshimura et al., 2008]. Characterization of AvBD expression profiles by Ebers et al. has
shown that both AvBD-2 and AvBD-6 are induced by Salmonella and AvBD-12 is
consitutively expressed [Ebers et al., 2009]. Data from the present study demonstrate that
the two Salmonella-inducible cationic peptides, AvBD-2 and AvBD-6 had minimal
antimicrobial activity against S. enterica serovar Typhimurium, suggesting that the
induced expression of AvBD-2 and -6 genes is more likely a general response to
conserved bacterial components. Instead, AvBD-12, a less potent AvBD against other
bacterial species, has a slight advantage over AvBD-2 and AvBD-6 in inhibiting or
killing S. enterica serovar Typhimurium. Constitutive expression of AvBD-12 may be an
important innate defense mechanism against Salmonellae colonization in chicken
oviduct.
Moderate expression of AvBD-2 in both small and/or large intestine, weak
expression of AvbD-12 in large intestine, moderate to strong expression of AvBD-2 and
AvBD-6 in leukocytes, moderate expression of AvBD-2 and AvBD-6 in lung, and strong
expression of AvBD-12 in oviduct have been observed in chicken hosts [Harwig et al.,
1994; Lynn et al., 2004; Ohashi et al., 2005; Zhao et al., 2001; Sadeyen et al., 2004, and
Xiao et al., 2004]. These findings along with the antimicrobial data generated by the
present work suggest that AvBD-2 and AvBD-6 are essential to clearing systemic
infections and AvBD-12 is important to control Salmonella colonization in reproductive
tract.
In summary, we have expressed and purified rAvBD-2, rAvBD-6, rAvBD-12 and
determined their antimicrobial activities under different pH conditions. Comparative
characterization of these AvBDs has provided new insight into the mechanisms
governing AvBD-mediated innate immune defense in chickens. These data also suggest
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that AvBD-2, -6, and -12 could be utilized as antimicrobial agents under both in vivo and
in vitro conditions.
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1.

Media for chemical-complement cells
1.1

Luria Bertani (LB) medium
BactoTM Tryptone

10 g/L

BBLTM Yeast Extract

5 g/L

Sodium Chloride (NaCl)
1.2

10 g/L

SOB medium
BactoTM Tryptone

20 g/L

BBLTM Yeast Extract

5 g/L

Sodium Chloride (NaCl)

0.5 g/L

Potassium Chloride (KCl)
2.

0.186 g/L

Buffers for SDS-PAGE
2.1

2mol/L Tris-HCl (pH 8.8)
Tris

242 g/L

HCl adjust pH to 8.8.
2.2

1mol/L Tris-HCl (pH 6.8)
Tris

121 g/L

HCl adjust pH to 6.8.
2.3

10% Lauryl Sodium Sulfate (SDS)
SDS

2.4

100 g/L

30% (w/v) Acrylamide / 0.8% (w/v) Bis-Acrylamide
Acrylamide

292 g/L

Bis-acrylamide

8 g/L
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2.5

10% Ammonium persulfate
Ammonium persulfate

2.6

100 g/L

2.5*Separating gel Buffer
2mol/L Tris-HCl (pH 8.8)

470 ml/L

10% SDS Solution

25 ml/L

Distilled Water
2.7

505 ml/L

5*Stacking gel Buffer
1mol/L Tris-HCl (pH 6.8)

625 ml/L

10% SDS Solution

50 ml/L

Distilled Water
2.8

325 ml/L

Electrophoresis Buffer
Tris

3 g/L

Glycine

14.4 g/L

SDS
2.9

1 g/L

12% Acrylamide gel
30% Acrylamide / 0.8% bis-acrylamide stock solution

3300 µl

2.5*Separating gel Buffer

3300 µl

Distilled Water

1650 µl

TEMED (N,N,N',N'-tetramethylethylenediamine)

7.5 µl

10% Ammonium persulfate

75 µl
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2.10

5% Stacking gel
30% Acrylamide/0.8%bis-acrylamide stock solution

420 µl

5*Stacking gel Buffer

495 µl

Distilled Water

1500 µl

TEMED (N,N,N', '-tetramethylethylenediamine)
10% Ammonium persulfate
3.

3 µl
22.5 µl

Buffers for Western Blot
3.1

Transfer Buffer
Tris

3.03 g/L

Glycine

14.4 g/L

Methanol
3.2

200 ml/L

Phosphate-Buffered Saline (PBS)
NaCl

8 g/L

KCl

3.3

0.2 g/L

Na2HPO4

1.42 g/L

KH2PO4

0.25 g/L

PBST Buffer
NaCl

8 g/L

KCl

0.2 g/L

Na2HPO4

1.42 g/L

KH2PO4

0.25 g/L

Tween-20

500 µl
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3.4

Blocking Buffer:
NaCl

8 g/L

KCl

4.

0.2 g/L

Na2HPO4

1.42 g/L

KH2PO4

0.25 g/L

Tween-20

500 µl

Non-Fat Milk

50 g/L

Buffers for protein purification by using Ni-NTA Anti-His protein superflow

columns
4.1

Buffer B
NaH2PO4

13.8 g/L

Tris

1.3 g/L

Urea

420 g/L

Adjust pH to 8.0 using NaOH
4.2

Buffer C
NaH2PO4

13.8 g/L

Tris

1.3 g/L

Urea

420 g/L

Adjust pH to 6.3 using HCl
4.3

Buffer E:
NaH2PO4

13.8 g/L

Tris

1.3 g/L
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Urea

480 g/L

Adjust pH to 4.5 using HCl
5.

Dialysis buffer (pH 8.0)
5.1

5.2

5.3

5.4

6M Urea dialysis buffer
Urea

360 g/L

NaCl

30 g/L

Tris

2.5 g/L

4M Urea dialysis buffer
Urea

240 g/L

NaCl

30 g/L

Tris

2.5 g/L

2M Urea dialysis buffer
Urea

120 g/L

NaCl

30 g/L

Tris

2.5 g/L

0M Urea dialysis buffer
NaCl

30 g/L

Tris

2.5 g/L
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1.

Extraction of RNA from cells using TRIzol:
1.1

Discard supernatant, add 1000 µl Trizol, and incubate at room temperature for
5 minutes.

1.2

Mix cell lysate with 200 µl chloroform in a 1.5 ml eppendorf centrifuge tube
and incubate at room temperature for 2 minutes.

1.3

Centrifuge at 12, 000 rpm for 15 minutes at 4°C.

1.4

Transfer upper layer into a new 1.5 ml centrifuge tube.

1.5

Add equal volume isopropanol and incubate on ice for 10 minutes.

1.6

Centrifuge at 12, 000 rpm for 15 minutes at 4°C.

1.7

Discard supernatant, add 500 µl 75% ETOH along the tube wall. Do not mix
or vortex.

1.8

Centrifuge at 7, 500 rpm for 5 minutes at 4°C.

1.9

Diacard supernatant and place tubes in a fume hood, air dry for 5-10 minutes.

1.10

Resuspend RNA in 50 µl DNase and RNase free water.

2.

Re-extraction RNA using phenol-chloroform.
2.1

The volume of the RNA should be over 100 µl, if not, add RNase-DNase free
water to at least 100 µl.

2.2

Add phenol to the RNA solution as 1:1 (v/v), and mix well.

2.3

Centrifuge at 13,000 rpm for 5 minutes and transfer the upper layer to a new
tube.

2.4

Add chloroform to the RNA solution as 1:1 (v/v), and mix well.
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2.5

Centrifuge at 13,000 rpm for 5 minutes and transfer the upper layer to a new
tube.

2.6

Add equal volume of Isopropanol into RNA solution and 1/10 volume of
sodium acetate (2 M pH 4.0), mix well.

2.7

Centrifuge at 13,000 rpm for 15 minutes at 4°C. Discard supernatant.

2.8

Add 500 µl 70% ETOH without touching the RNA pellet. Centrifuge at
13,000 rpm for 10 minutes 4°C.

2.9

Air dry. Apply appropriate amount of RNase-DNase free water to elute the
RNA.

3

Reverse transcription reaction:
3.1

Mixture 1
RNA

15 µl

10*RT buffer

5 µl

MgCl2

5 µl

DNase I (2 Units)

1 µl

RNase Inhibitor

1 µl

Total volume

27 µl

Mixture 1 was incubated in room temperature for 15 minutes, and incubated at
75°C for 15 minutes to inactivate DNase I.
3.2

Mixture 2
DNase RNase free water

13.5 µl
53

RNase Inhibitor

1 µl

dNTPs

4 µl

Hexamer

3 µl

Reverse Transcriptase (150 Units)

1.5 µl

Total volume

23 µl

Combine Mixture 1 and 2 when mixture 1 reaches room temperature. The
final volume is 50 µl.
3.3

4.

Program:
25°C

10 minutes

48°C

45 minutes

95°C

10 minutes

PCR reaction systems:
4.1

Reagents
cDNA template

5 µl

10x Buffer

5 µl

MgCl2

5 µl

dNTPs

3 µl

Taq Polymerase

1 µl

DNase free water

27 µl

Forward primer (100pmol/µl)

2 µl

Reverse primer (100pmol/µl)

2 µl
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Final volume
4.2

50 µl

Amplification condition:
Stage

Temperature

Time (minute)

Repeat

1

95°C

3:00

1

2

95°

0:30
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(AvBD-2) 55°C

0:20

(AvBD-6) 52°C

0:20

(AvBD-12) 51°C

0:20

(AvBD-12) 56°C

0:20

72°C

00:30

72°C

5:00

3

5.

PCR-screening of cloned insert
5.1

Reagents
DNA template

1 µl

10x Buffer

2 µl

MgCl2

2 µl

dNTPs

0.75 µl

Taq Polymerase

0.25 µl

DNase free water

13 µl

Forward primer (100pmol/µl)

0.5 µl

Reverse primer (100pmol/µl)

0.5 µl
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Final volume
5.2

20 µl

Amplification condition:
Stage

Temperature

Time (minute)

Repeat

1

95°C

5:00

1

2

95°

0:10

40

50°C

0:20

72°C

0:30

72°C

5:00

3

6. Purification of DNA from agarose gel by using the Wizard® PCR prep DNA
purification system from Promega:
6.1

Separate PCR product by gel electrophoresis.

6.2

Excise DNA band with expected size.

6.3

Place the agarose slice in a 1.5 ml eppendorf centrifuge tube containing 1 ml
resin.

6.4

Incubate at 56°C until the agarose is dissolved.

6.5

Prepare a Wizard® Minicolumn by attaching the syringe barrel to a
minicolumn and inserting the minicolumn/syringe barrel into a vaccum
manifold.

6.6

Add resin/DNA mixture to the syringe Barrel.

6.7

Apply vaccum to pull liquid through the Minicolumn. Release vaccum when
all the liquid has passed through the Minicolumn.
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6.8

Add 2 ml of 80% isopropanol to the syringe Barrel. Apply vaccum to pull
solution through the Minicolumn.

6.9

Dry the resin by continuing to apply the vaccum for 25 seconds.

6.10

Remove the syringe Barrel and transfer the minicolumn to a 1.5 ml
microcentrifuge tube.

6.11

Centrifuge at 10,000g for 2 minutes and transfer the Minocolumn to a clean
1.5 ml microcentrifuge tube.

6.12

Add 20 µl preheated Nuclease-Free H20 to minicolumn and wait 2 minutes.

6.13

Elute the DNA by centrifuging at 10,000g for 20 seconds at room tempature.

6.14

Remove and discard minicolumn, store DNA at -20°C or use immediately.

7.0

TOPO TA cloning (Invitrogen) and chemical transformation:
7.1

Gently mix 4 µl fresh PCR product, 1 µl Salt solution from the kit, and 1 µl
pCR2 TOPO vector.

7.2

Incubate at room temperature for 30 min.

7.3

Add the mixture to a vial of One Shot® E. coli Top 10.

7.4

Incubate on ice for 30 min.

7.5

Heat-shock the cells by incubating the mixture at 42°C for 30 sec.

7.6

Transfer the tube immediately onto ice and add 250 µl of room temperature
S.O.C. medium followed by shaking at 37°C for one hour.

7.7

Spread 100µl culture on a pre-warmed LB plate containing ampicillin 100
µl/ml and X-gal 30 µg/ml.

7.8

Incubate the culture plate at 37°C for 16 hours.
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8

7.9

Pick white colonies and subculture onto new plates.

7.10

PCR screening for insert.

Plasmid extraction by using Wizard® Plus Minipreps DNA Purification system
from Promega:
8.1

Resuspend a full loop (10 µl inoculation loop) of bacterial colonies in 400 µl
Cell Resuspension Solution in a 1.5 ml centrifuge tube.

8.2

Add 400 µl Cell Lysis Solution, mix by inverting the tube 4 times, and
incubate at room temperature for 5 minutes.

8.3

Add 400 µl of Neutralization Solution, mix by inverting the tube 4 times, and
incubate on ice for 5 minutes.

8.4

Centrifuge the bacterial lysate at 10,000 rpm for 5 minutes.

8.5

Attach a syringe barrel to a minicolumn, insert the tip of the
minicolumn/syringe barrel assembly into the vacuum manifold.

8.6

Thoroughly mix the DNA purification resin and transfer 1ml into each barrel.

8.7

Transfer bacterial lystate to the barrel containing resin.

8.8

Open the stopcocks and apply a vacuum to pull the resin and lysate mix into
minicolumn. When all liquid has completely passed through column, break
the vacuum.

8.9

Add 2 ml of the column wash solution to the barrel and reapply the vacuum to
draw the solution through the minicolumn.

8.10

Dry the resin by continuing to draw a vacuum for 25 seconds.

8.11

Remove the barrel and transfer the minicolumn to a 1.5 ml centrifuge tube.
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8.12

Centrifuge at 10,000 rpm for 2 min to remove any residual column wash
solution.

8.13

Transfer minicolumn to a new centrifuge tube.

8.14

Add 50 µl preheated Nuclease-Free H20 to minicolum and wait for 2 min.

8.15

Centrifuge at 10,000 rpm for 20 seconds to elute DNA.

8.16

The DNA can be used immediately or saved in -20°C for lone term storage.

9.

Restriction enzyme, BamH I and Kpn I, digestion:
9.1

Reagents:
Plasmid DNA

20 µl

10* Multicore Buffer

6 µl

BSA

0.5 µl

BamH I

3 µl

Kpn I

3 µl

DNase-RNase-free water

27.5 µl

Final volume

9.2

10.

60 µl

Incubated in a water bath 37°C for 1.5 hours.

Ligation using T4 ligase from Invitrogen:
10.1

Reaction system (all the buffers and enzymes are from the T4 Ligation kit)
pRSET A

10 µl
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10.2

11.

AvBDs’ DNA insert

10 µl

5X Buffer

2.5 µl

T4 ligase

0.1 µl

DNase-RNase-free water

2.4 µl

Final volume

25 µl

Incubated at room temperature for 2 hours.

Preparation of competent cells BL21(DE3)PlysS and Top10F′:
11.1

Culture Top10F’ and BL21(DE3)PlysS on LB agar containing the desired
antibiotics. (Top10F′: 10 µg/ml Tetracycline, BL21(DE3)PlysS: 30 µg/ml
chloramphenicol. )

11.2

Inoculate individual colonies into SOB medium (100 ml).

11.3

Incubate at 37°C with vigorous shaking (230 cycles/minute).

11.4

When OD600 reaches approximately 0.5, transfer culture into 50ml prechilled tubes.

11.5

Centrifuge at 4,500 rpm for 10 min at 4°C.

11.6

Discard medium and put tube up side down for 1 min.

11.7

Resuspend each bacterial pellet in 10 ml of ice-cold 50 mM CaCl2.

11.8

Keep bacterial suspension on ice for at least 30 min.

11.9

Centrifuge the CaCl2-treated cells at 4500 rpm for 10 min at 4°C.

11.10 Discard medium and gently resuspend each pellet in 2 ml of ice-cold
50 mM CaCl2.
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11.11 Keep bacteria on ice.
11.12 Aliquot 100 µl of CaCl2-treated cells into pre-chilled 1.5 ml centrifuge tubes.
11.13 Store at -80°C.

12.

13.

14.

Genomic DNA electrophoresis:
12.1

Mix genomic DNA with DNA loading buffer (Sigma).

12.2

Loaded into 1% agarose gel.

12.3

Electrophoresis at 125 V until the front dye goes to the middle of the gel.

RNA electrophoresis:
13.1

Mix RNA with RNA loading buffer (Sigma).

13.2

Loaded into 1.5% agarose gel.

13.3

Electrophoresis at 125 V until the front of dye goes to the middle of the gel.

Phenol-chloroform purification of DNA:
14.1

The volume of the DNA should be over 100 µl, if not, add RNase-DNase free
water to at least 100 µl.

14.2

Add phenol to the DNA solution as 1:1 (v/v), and mix well.

14.3

Centrifuge at 13,000 rpm for 5 minutes, and transfer the upper layer to a new
tube.

14.4

Add chloroform to the DNA solution as 1:1 (v/v), and mix well.

14.5

Centrifuge at 13,000 rpm for 5 minutes, and transfer the upper layer to a new
tube.
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14.6

Add isopropanol into DNA solution as 1:1 (v/v), and also add sodium Acetate
(2 M pH 4.0) as 1:10 (v/v).

14.7

Incubate at -20°C for 10 minutes, and centrifuge at 13,000 rpm for 15
minutes. Discard the liquid.

14.8

Add 70% ETOH without touching the DNA pellet by tip. Centrifuge at 13,000
rpm for 10 minutes.

14.9

Air dry. Apply appropriate amount of RNase-DNase free water to elute the
DNA.

14.10 Use DNA immediately or store at -20°C.

15.

Transformation of Top10F′ with pRSET A
15.1

Mix e 3 µl plasmid DNA pRSET A (0.5 µg/µl) with of 100 µl Top10F’
competent cell and add.

15.2

Incubate cell on ice for 30 min.

15.3

Heat shock cells at 42°C for 45 sec and return cell tube to ice for 2 min.

15.4

Add 250 µl SOC medium and incubate the cultures for 45 min at 37°C with
vigorous shaking (235 cycles/min).

15.5

Plate 50 µl cells to LB plate containing 100 µg/ml Ampicillin for selection of
plasmid pRSET A.

15.6

16.

Incubate plate at 37°C overnight.

Transformation of BL21(DE3)PlysS with plasmids pRSET A-AvBD-2, -6, and -

12.
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16.1

Mix 3 µl plasmid DNA with 100 µl BL21(DE3)PlysS competent cell.

16.2

Incubate on ice for 30 min.

16.3

Heat shock cells at 42°C for 45 sec and place the cells on ice for 2 min.

16.4

Add 250 µl SOC medium and incubate for 45 min at 37°C with vigorous
shaking (235 cycles/min).

16.5

Plate 50 µl cells onto a LB plate containing 100 µg/ml Ampicillin and 30
µl/ml Chloramphenicol for selection of plasmid pRSET A-AvBD-2, -6 and 12.

16.6

17.

Incubate plate at 37°C overnight.

SDS-PAGE Gel and Western blot:
17.1

Mix Protein 1:1 with SDS-Sample Buffer and heat at approximately 100°C for
5 min.

17.2

Run on an SDS-PAGE minigel until the blue dye is at the bottom of the gel.

17.3

Cut the nitrocellulose membrane and the filter paper to the size of the gel.

17.4

Equilibrate the gel and wet the membrane, filter paper, and fiber pads in
transfer buffer for at least 15 min.

17.5

Assemble the “gel sandwich” as follows: the cassette with gray side down,
fiber pad, filter paper, gel, membrane, filter paper, fiber pad.

17.6

Put the “gel sandwich” in tank and make sure the protein would be transferred
electrically from the negative pole to the positive pole.

17.7

Add cooling unit and transfer buffer (completely fill tank).

17.8

Transfer at 125 V, 0.35 A for 1.5 hour.
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17.9

Rinse membrane three times in PBS.

17.10 Block the membrane for one hour in blocking buffer at room temperature on a
shaker.
17.11 Rinse membrane three times in PBS and transfer membrane to a tray
containing Anti-Xpress Antibody diluted 1:5000 to 10 ml blocking buffer.
17.12 Incubate with gentle agitation for one hour at room temperature.
17.13 Transfer membrane to a tray containing PBST and wash three times.
17.14 Transfer membrane to a tray containing Anti-mouse IgG-HRP conjugate with
1:500 dilutions and incubated one hour with gentle agitation.
17.15 Transfer membrane to a tray containing PBST and wash three times.
17.16 Mix the first solution (15 mg 4-chloro-1-naphthol in 5 ml cold methanol) with
the second solution (30 µl 30% hydrogen peroxide in 25 ml PBS) and pour
gently onto the membrane.

18.

Recombinant peptide purification:
18.1

Thaw BL21(DE3)PlysS cell pellet on ice and resuspended in “Buffer B”.

18.2

Gently shake one hour at room temperature until the lysis is complete (the
solution becomes translucent).

18.3

Sonicat for 10 times, 5 sec. each time.

18.4

Centrifuge lysate at 10,000 x g for 30 minutes at room temperature to pellet
cellular debris.

18.5

Collect supernatant containing solubilized hexahistidine-tagged recombinant
peptides and transfer into a fresh tube.
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18.6

Position the Ni-NTA superflow column on the rack.

18.7

Remove the storage buffer from above the resin either by using a pipette or by
allowing it to drain through by gravity flow.

18.8

Equilibrate the column by pipetting 10 ml “Buffer B” into column, and
allowing it to drain through completely by graving flow.

18.9

Transfer the cleared lysates into the equilibrated columns and allow the
columns to drain by gravity flow.

18.10 Perform the first wash step by pipetting 10 ml “Buffer B” into each column.
Allow the buffer to drain through completely by gravity flow.
18.11 Perform a second wash step by pipetting 10 ml “Buffer C” unto each column.
Allow the buffer to drain through completely by gravity flow.
18.12 Place an elution vessel under column outlet.
18.13 To elute the hexahistidine-tagged peptides, pipette 3 ml “Buffer E” urea into
each column. Allow buffer to flow through completely, and collect flowthrough in the elution vessels.
18.14 Elute again with 3 ml “Buffer E”.

19.

Extensive dialysis of recombinant peptides:
19.1

Remove the Slide-A-Lyzer Cassette from its pouch and immerse it in 8 M
dialysis buffer. Hydrate for 10 – 15 minutes.

19.2

Remove cassette from buffer and remove excess liquid by tapping the edge of
the cassette gently on paper towels.
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19.3

Fill the syringe with the recombinant peptide, leaving a small amount of air in
the syringe.

19.4

With the bevel sideways, insert the tip of needle through one of the syringe
ports located at a top corner of the cassette.

19.5

Inject peptide slowly. Withdraw air by pulling up to the syringe piston.

19.6

Remove the syringe needle from the cassette while retaining air in the syringe.

19.7

Float the cassette in the 8 M dialysis solution.

19.8

Dialyze for at least 2 hours at room temperature.

19.9

Change the dialysis buffer to 6 M dialysis buffer and dialyze for 2 hours at
room temperature.

19.10 Change the dialysis buffer to 4 M dialysis buffer and dialyze for 2 hour at
room temperature.
19.11 Change the dialysis buffer to 2 M dialysis buffer and dialyze for 2 hour at
room temperature.
19.12 Change the dialysis buffer to 0 M dialysis buffer and dialyze for 2 hour at
room temperature.
19.13 To remove peptides, fill syringe with a volume of air at least equal to the
peptide size.
19.14 Penetrate the gasket with the needle through a top, unused syringe guide port.
Discharge air into cassette cavity to separate membranes, which prevents
needle penetration of the membrane.
19.15 Turn the unit so that needle is on the bottom and allow the peptide to collect
near the port. Withdraw the peptide into the syringe.
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19.16 Inject the peptide slowly into a fresh tube, store peptide at -80℃.
Abbreviations:
CAMPs, Cationic antimicrobial peptides; CDC, Centers for disease Control;
AvBD, Avian β-defensin; ATCC: American type collection; RT-PCR, reverse
transcriptase polymerase chain reaction; UTR, untranslated region; aa, amino acid; KDa,
Kilodalton; GI tract, Gastrointestinal tract.
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